Objective. To conduct a comprehensive pharmacoeconomic evaluation of feasibility of treatment with Cariprazine (Reagila) in patients with schizophrenia. Materials and methods. A retrospective study using the pharmacoeconomic cost analysis, budget impact analysis, and cost-effectiveness analysis was performed. Data on Cariprazine were compared to those on Sertindole. Results. If Cariprazine is used instead of Sertindole, the cost saved will amount to 30.8% per patient per year. If sertindole is fully replaced with cariprazine, the costs related to treatment of patients with a second generation antipsychotics funded by the state will be reduced by 97.8 million rubles over 3 years (30.9%). Gradual replacement of Sertindole with Cariprazine will make it possible to reduce budget expenditures by 20.1% or 63.8 million rubles over 3 years. This replacement will make it possible to provide therapy to additional 44.6% of patients, or 561 people. In this case, the number of patients receiving therapy will increase from 1257 to 1818. Conclusion. The results of the pharmacoeconomic analysis show that the registration of Cariprazine (Reagila) in the Russian Federation as therapeutic drug is economically feasible. © I.N. DYAKOV, S.K. ZYRYANOV.